Dengue is a global health concern that is growing rapidly. Among dengue threat areas, around 2.5 billion people live with about 100 million new cases worldwide each year. The WHO study indicates that deaths in untreated cases of dengue fever were as high as 20%, while inpatients had a death rate of less than 1%. In particular, the female Aedes-genus mosquito transmits the dengue virus. The patient experiences symptoms such as heavy fever, nausea, vomiting, muscle, and vocal pains and bodily fluid falls. The findings of previous research studies have shown that both dengue fever and dengue hemorrhagic fever can cause severe thrombocytopenia. This is one of the dengue hemorrhagic fever diagnostic criteria. The primary outcome of dengue, therefore, lies in avoiding thrombocytopenia, correcting the excess in body fluid and delivering symptomatic care. There are many different treatments available to increase the number of platelets, which have their own advantages and disadvantages addressed. In this research, we focused primarily on how the number of platelets in dengue patients decreases? And how can the leaf extract treat the patient with dengue for thrombocytopenia? When patients are relying on papaya leaves and experiencing good results, some extensive research should be conducted in humans to make this drug available to all patients.